These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19635228)

  • 21. Medical treatment of neuroendocrine gut and pancreatic tumors.
    Oberg K; Eriksson B
    Acta Oncol; 1989; 28(3):425-31. PubMed ID: 2472826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
    Bomanji JB; Papathanasiou ND
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
    Makis W; McCann K; Bryanton M; McEwan AJ
    Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.
    Pathirana AA; Vinjamuri S; Byrne C; Ghaneh P; Vora J; Poston GJ
    Eur J Surg Oncol; 2001 Jun; 27(4):404-8. PubMed ID: 11417988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
    Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
    Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
    J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
    Prvulovich EM; Stein RC; Bomanji JB; Ledermann JA; Taylor I; Ell PJ
    J Nucl Med; 1998 Oct; 39(10):1743-5. PubMed ID: 9776280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
    Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
    Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Li L; Ma J; Yang S; Zhang C
    Hell J Nucl Med; 2024; 27(1):64-65. PubMed ID: 38629819
    [No Abstract]   [Full Text] [Related]  

  • 36. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
    Leong WL; Pasieka JL
    J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
    Oberg K; Eriksson B
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-DOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid.
    Singla S; Gupta S; Reddy RM; Durgapal P; Bal CS
    Jpn J Clin Oncol; 2012 Dec; 42(12):1202-6. PubMed ID: 23107835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.